Boston Scientific Faces Cardiovascular Test in Q1 Earnings

Robust performance in Cardiovascular and steady MedSurg growth expected to drive solid revenue and earnings gains.

Apr. 17, 2026 at 6:40pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a polished metal stent device and a sleek medical monitor on a clean, monochromatic background, conceptually representing the advanced cardiovascular technology of Boston Scientific.A minimalist, high-tech still life captures the precision and innovation behind Boston Scientific's cardiovascular devices.Boston Today

Boston Scientific, the renowned medical device manufacturer, is set to report its Q1 2026 earnings. The company has consistently beaten earnings estimates in the past four quarters, with an average surprise of 6.08%. Analysts expect the Cardiovascular division, particularly the Interventional Cardiology & Vascular Therapies unit, to deliver another stellar performance, driven by strong growth in the coronary therapies franchise and continued momentum in the WATCHMAN device. The MedSurg segment is also expected to maintain its steady growth trajectory, with the Urology and Neuromodulation businesses contributing positively.

Why it matters

Boston Scientific's Q1 earnings report will provide insights into the company's ability to capitalize on the robust demand for its cardiovascular products and sustain its growth momentum across its diversified medical device portfolio. Strong performance in this quarter could further solidify the company's position in the competitive medical technology market.

The details

Within the Cardiovascular division, the Interventional Cardiology & Vascular Therapies unit is expected to have gained from strong growth in the coronary therapies franchise, supported by the AGENT Drug-Coated Balloon. The WATCHMAN device is also expected to have contributed significantly, with robust adoption driving continued market share gains. In the Cardiac Rhythm Management business, sales might have benefited from the addition of complementary bioenvelope and ongoing momentum within the Diagnostics business. The Peripheral Interventions unit is likely to have been driven by the performance in Transcarotid Artery Revascularization (TCAR) and continued strength in Varithena and EkoSonic Endovascular System (EKOS). The Interventional Oncology & Embolization business and the Electrophysiology unit are also expected to have contributed positively.

  • Boston Scientific is set to report its Q1 2026 earnings on April 17, 2026.

The players

Boston Scientific Corporation

A leading medical device manufacturer that develops and manufactures a wide range of products for use in various interventional medical specialties, including interventional cardiology, peripheral interventions, cardiac rhythm management, electrophysiology, neurovascular intervention, and endoscopy.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Boston Scientific's Q1 2026 earnings report to gauge the company's ability to maintain its strong performance in the Cardiovascular division and sustain growth across its diversified medical device portfolio. The company's guidance for the remainder of the year will also be a key focus for analysts and investors.

The takeaway

Boston Scientific's Q1 2026 earnings report will be a crucial indicator of the company's ability to capitalize on the robust demand for its cardiovascular products and continue its growth momentum across its diversified medical device business. Strong performance in this quarter could further solidify the company's position in the competitive medical technology market.